BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 23461807)

  • 1. Multiple endocrine neoplasia type 2A due to an exon 8 (G533C) mutation in a large North American kindred.
    Castro MR; Thomas BC; Richards ML; Zhang J; Morris JC
    Thyroid; 2013 Dec; 23(12):1547-52. PubMed ID: 23461807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The RET p.G533C mutation confers predisposition to multiple endocrine neoplasia type 2A in a Brazilian kindred and is able to induce a malignant phenotype in vitro and in vivo.
    Oliveira MN; Hemerly JP; Bastos AU; Tamanaha R; Latini FR; Camacho CP; Impellizzeri A; Maciel RM; Cerutti JM
    Thyroid; 2011 Sep; 21(9):975-85. PubMed ID: 21834681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple endocrine neoplasia type 2A in two families with the familial medullary thyroid carcinoma associated G533C mutation of the RET proto-oncogene.
    Peppa M; Boutati E; Kamakari S; Pikounis V; Peros G; Panayiotides IG; Economopoulos T; Raptis SA; Hadjidakis D
    Eur J Endocrinol; 2008 Dec; 159(6):767-71. PubMed ID: 18805915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High prevalence of exon 8 G533C mutation in apparently sporadic medullary thyroid carcinoma in Greece.
    Sarika HL; Papathoma A; Garofalaki M; Vasileiou V; Vlassopoulou B; Anastasiou E; Alevizaki M
    Clin Endocrinol (Oxf); 2012 Dec; 77(6):857-62. PubMed ID: 22676047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A rare missense variant in RET exon 8 in a Portuguese family with atypical multiple endocrine neoplasia type 2A.
    Martins AF; Martins JM; do Vale S; Dias T; Silveira C; da Silva IR; Carmo-Fonseca M
    Hormones (Athens); 2016 Jul; 15(3):435-440. PubMed ID: 27838608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
    Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple endocrine neoplasia 2A due to a unique C609S RET mutation presents with pheochromocytoma and reduced penetrance of medullary thyroid carcinoma.
    Kinlaw WB; Scott SM; Maue RA; Memoli VA; Harris RD; Daniels GH; Porter DM; Belloni DR; Spooner ET; Ernesti MM; Noll WW
    Clin Endocrinol (Oxf); 2005 Dec; 63(6):676-82. PubMed ID: 16343103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A (Sipple's syndrome).
    Oishi S; Sato T; Takiguchi-Shirahama S; Nakamura Y
    Endocr J; 1995 Aug; 42(4):527-36. PubMed ID: 8556060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Features of a Family with Multiple Endocrine Neoplasia Type 2A Caused by the D631Y RET Mutation.
    Ospina NS; Maraka S; Donegan D; Morris JC
    Thyroid; 2017 Oct; 27(10):1332-1334. PubMed ID: 28747092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A comparison of clinical characteristics between 2 pedigrees of multiple endocrine neoplasia type 2A with different RET mutations].
    Weng Y; Xue SN; Zhang SL; Cheng H; Yan L
    Zhonghua Nei Ke Za Zhi; 2018 Feb; 57(2):134-137. PubMed ID: 29397600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic screening of patients with medullary thyroid cancer in a referral center in Greece during the past two decades.
    Sarika HL; Papathoma A; Garofalaki M; Saltiki K; Pappa T; Pazaitou-Panayiotou K; Anastasiou E; Alevizaki M
    Eur J Endocrinol; 2015 Apr; 172(4):501-9. PubMed ID: 25624014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nationwide French Study of RET Variants Detected from 2003 to 2013 Suggests a Possible Influence of Polymorphisms as Modifiers.
    Lebeault M; Pinson S; Guillaud-Bataille M; Gimenez-Roqueplo AP; Carrie A; Barbu V; Pigny P; Bezieau S; Rey JM; Delvincourt C; Giraud S; Veyrat-Durebex C; Saulnier P; Bouzamondo N; Chabbert M; Blin J; Mohamed A; Romanet P; Borson-Chazot F; Rohmer V; Barlier A; Mirebeau-Prunier D
    Thyroid; 2017 Dec; 27(12):1511-1522. PubMed ID: 28946813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients with RET D631Y mutations most commonly present with pheochromocytoma and not medullary thyroid carcinoma.
    Elston MS; Meyer-Rochow GY; Holdaway I; Conaglen JV
    Horm Metab Res; 2012 May; 44(5):339-42. PubMed ID: 22274720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The clinical patterns and RET proto-oncogene in fifteen multiple endocrine neoplasia type 2A pedigrees].
    Zhou YL; Zhu SX; Li JJ; Liu JB; Yin M; Xiao BY; Yu CL; Wang LM; Gu LQ; Cui B; Ning G; Li XY; Zhao YJ
    Zhonghua Nei Ke Za Zhi; 2007 Jun; 46(6):466-70. PubMed ID: 17663821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Catecholamine crisis as a first manifestation of familial bilateral pheochromocytoma caused by RET proto-oncogene mutation in codon C 634R.
    Zwolak A; Rudzki G; Świrska J; Dudzińska M; Daniluk J; Tarach J
    Endokrynol Pol; 2015; 66(5):462-8. PubMed ID: 26457501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical spectrum of multiple endocrine neoplasia type 2a caused by the rare intracellular RET mutation S891A.
    Schulte KM; Machens A; Fugazzola L; McGregor A; Diaz-Cano S; Izatt L; Aylwin S; Talat N; Beck-Peccoz P; Dralle H
    J Clin Endocrinol Metab; 2010 Sep; 95(9):E92-7. PubMed ID: 20554711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical features and mutations of RET proto-oncogene in a pedigree affected with type 2A multiple endocrine neoplasia].
    Zhang Y; Zheng X; Cheng L; Ma S
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2017 Feb; 34(1):106-109. PubMed ID: 28186607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.
    Elisei R; Romei C; Cosci B; Agate L; Bottici V; Molinaro E; Sculli M; Miccoli P; Basolo F; Grasso L; Pacini F; Pinchera A
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4725-9. PubMed ID: 17895320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 6-Base Pair in Frame Germline Deletion in Exon 7 Of RET Leads to Increased RET Phosphorylation, ERK Activation, and MEN2A.
    Latteyer S; Klein-Hitpass L; Khandanpour C; Zwanziger D; Poeppel TD; Schmid KW; Führer D; Moeller LC
    J Clin Endocrinol Metab; 2016 Mar; 101(3):1016-22. PubMed ID: 26765577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RET proto-oncogene testing in infants presenting with Hirschsprung disease identifies 2 new multiple endocrine neoplasia 2A kindreds.
    Fialkowski EA; DeBenedetti MK; Moley JF; Bachrach B
    J Pediatr Surg; 2008 Jan; 43(1):188-90. PubMed ID: 18206480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.